Phase I/II trial of melanoma therapy with dendritic cell tumor-mRNA

Cancer Gene Therapy

13, 905-918

DOI: 10.1038/sj.cgt.7700961

Citation Report

#	Article	IF	Citations
1	Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunology, Immunotherapy, 2006, 55, 1432-1442.	2.0	78
2	Immunoregulatory dendritic cells to prevent and reverse new-onset Type 1 diabetes mellitus. Expert Opinion on Biological Therapy, 2007, 7, 951-963.	1.4	20
3	T-Cell Distribution and Adhesion Receptor Expression in Metastatic Melanoma. Clinical Cancer Research, 2007, 13, 2549-2556.	3.2	64
4	Dendritic cells for active immunotherapy: Optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine, 2007, 25, B47-B60.	1.7	47
5	Vaccine therapy for melanoma: Current status and future directions. Vaccine, 2007, 25, B4-B16.	1.7	84
6	mRNA transfection of DC in the immature or mature state: comparable in vitro priming of Th and cytotoxic T lymphocytes against DC electroporated with tumor cell line-derived mRNA. Cytotherapy, 2007, 9, 587-592.	0.3	6
7	Current Immunotherapeutic Strategies in Malignant Melanoma. Surgical Oncology Clinics of North America, 2007, 16, 945-973.	0.6	5
8	Cancer Immunotherapy: Challenges and Opportunities. , 2007, , 167-181.		2
9	A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines. BMC Cancer, 2007, 7, 119.	1.1	50
10	T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunology, Immunotherapy, 2007, 56, 659-675.	2.0	60
11	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2007, 56, 1513-1537.	2.0	149
12	Adhesion molecules in cutaneous immunity. Seminars in Immunopathology, 2007, 29, 45-57.	2.8	12
13	Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunology Letters, 2008, 115, 33-42.	1.1	81
14	Immune Cell Recruitment and Cell-Based System for Cancer Therapy. Pharmaceutical Research, 2008, 25, 752-768.	1.7	35
15	Studies on mRNA Electroporation of Immature and Mature Dendritic Cells: Effects on their Immunogenic Potential. Molecular Biotechnology, 2008, 40, 151-160.	1.3	23
16	Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNAâ€electroporated B cells. European Journal of Immunology, 2008, 38, 2106-2117.	1.6	16
17	Dendritic cell vaccines in melanoma: From promise to proof?. Critical Reviews in Oncology/Hematology, 2008, 66, 118-134.	2.0	113
18	Induction of T-Cell Responses against Cutaneous T-Cell Lymphomas Ex Vivo by Autologous Dendritic Cells Transfected with Amplified Tumor mRNA. Journal of Investigative Dermatology, 2008, 128, 2631-2639.	0.3	23

#	Article	IF	Citations
19	Vaccination with Messenger RNA (mRNA). Handbook of Experimental Pharmacology, 2008, , 221-235.	0.9	107
20	Recent Advances in Cancer Vaccines: An Overview. Japanese Journal of Clinical Oncology, 2008, 39, 73-80.	0.6	62
22	Comparison of Î±-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine, 2008, 26, 2824-2832.	1.7	31
23	Immunopharmacology. , 2008, , .		6
24	Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook. Expert Review of Vaccines, 2008, 7, 1329-1339.	2.0	44
25	Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma. Journal of Immunotherapy, 2008, 31, 771-780.	1.2	87
26	Dendritic cell-based therapy in Type 1 diabetes mellitus. Expert Review of Clinical Immunology, 2009, 5, 325-339.	1.3	13
27	Dendritic cells: therapy and imaging. Expert Opinion on Biological Therapy, 2009, 9, 539-564.	1.4	20
28	Specific antitumor effects of tumor vaccine produced by autologous dendritic cells transfected with allogeneic osteosarcoma total RNA through electroporation in Rats. Cancer Biology and Therapy, 2009, 8, 973-980.	1.5	9
29	Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunology, Immunotherapy, 2009, 58, 1-14.	2.0	181
30	Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunology, Immunotherapy, 2009, 58, 1609-1626.	2.0	44
31	Cancer vaccination with telomerase peptide GV1001. Expert Opinion on Investigational Drugs, 2009, 18, 687-694.	1.9	70
32	Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine, 2009, 27, 2213-2219.	1.7	32
33	Cancer Immunotherapy. Topics in Companion Animal Medicine, 2009, 24, 130-136.	0.4	14
34	Dendritic cell vaccination as a treatment modality for melanoma. Expert Review of Anticancer Therapy, 2009, 9, 1631-1642.	1.1	19
35	Dendritic cells in the skin â€“ potential use for melanoma treatment. Pigment Cell and Melanoma Research, 2009, 22, 30-41.	1.5	14
36	Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity. Blood, 2009, 113, 4262-4272.	0.6	46
37	Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?. Expert Opinion on Biological Therapy, 2010, 10, 1539-1553.	1.4	19

#	Article	IF	Citations
38	Induction of cytotoxic T lymphocytes primed with Tumor RNA-loaded Dendritic Cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design. BMC Cancer, 2010, 10, 261.	1.1	20
39	Presentation of tumour antigens by dendritic cells and challenges faced. Current Opinion in Immunology, 2010, 22, 137-144.	2.4	42
40	When do I (not) release cellular products?. ISBT Science Series, 2010, 5, 141-147.	1.1	0
41	RNA Vaccines in Cancer Treatment. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-12.	3.0	37
42	Strategies for Cancer Vaccine Development. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-13.	3.0	102
43	Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opinion on Drug Delivery, 2010, 7, 1079-1093.	2.4	42
44	Dendritic cells as therapeutic agents against cancer. Frontiers in Bioscience - Landmark, 2010, 15, 321.	3.0	14
45	Cancer Immunotherapy. Veterinary Clinics of North America - Small Animal Practice, 2010, 40, 507-518.	0.5	14
46	Whole tumor antigen vaccines. Seminars in Immunology, 2010, 22, 132-143.	2.7	201
47	Human myeloid dendritic cells for cancer therapy: Does maturation matter?. Vaccine, 2010, 28, 5153-5160.	1.7	27
48	Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell and Melanoma Research, 2010, 23, 607-619.	1.5	42
49	The evolving role of dendritic cells in cancer therapy. Expert Opinion on Biological Therapy, 2010, 10, 369-379.	1.4	34
50	Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy, 2010, 12, 721-734.	0.3	66
51	A Short Pulse of IL-4 Delivered by DCs Electroporated With Modified mRNA Can Both Prevent and Treat Autoimmune Diabetes in NOD Mice. Molecular Therapy, 2010, 18, 2112-2120.	3.7	52
52	Melanoma vaccines: developments over the past 10 years. Expert Review of Vaccines, 2011, 10, 853-873.	2.0	27
53	Engineering Dendritic Cells to Enhance Cancer Immunotherapy. Molecular Therapy, 2011, 19, 841-853.	3.7	103
54	Dendritic cellâ€“tumor cell hybrids and immunotherapy: what's next?. Cytotherapy, 2011, 13, 774-785.	0.3	15
55	Vaccine therapy for metastatic melanoma. Melanoma Research, 2011, 21, 165-174.	0.6	36

#	Article	IF	Citations
56	Therapeutic cancer vaccines: are we there yet?. Immunological Reviews, 2011, 239, 27-44.	2.8	249
57	Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Therapy, 2011, 18, 584-593.	2.3	41
58	Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Therapy, 2011, 18, 702-708.	2.3	150
59	Extracellular domain of human 4-1BBL enhanced the function of cytotoxic T-lymphocyte induced by dendritic cell. Cellular Immunology, 2011, 271, 118-123.	1.4	8
60	In Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles. Molecular Pharmaceutics, 2011, 8, 774-787.	2.3	226
61	Route of Administration Modulates the Induction of Dendritic Cell Vaccineâ€“Induced Antigen-Specific T Cells in Advanced Melanoma Patients. Clinical Cancer Research, 2011, 17, 5725-5735.	3.2	158
62	Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunology, Immunotherapy, 2011, 60, 457-466.	2.0	102
63	hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunology, Immunotherapy, 2011, 60, 809-818.	2.0	85
64	Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 445-453.	1.7	192
65	Tumor vaccination using messenger RNA: prospects of a future therapy. Current Opinion in Immunology, 2011, 23, 399-406.	2.4	114
66	Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy, 2011, 3, 517-537.	1.0	57
67	Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients. Clinical Cancer Research, 2011, 17, 4568-4580.	3.2	105
68	State of the Art in Tumor Antigen and Biomarker Discovery. Cancers, 2011, 3, 2554-2596.	1.7	38
69	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clinical Cancer Research, 2012, 18, 5460-5470.	3.2	86
70	Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. OncoImmunology, 2012, 1, 287-357.	2.1	24
71	mRNA as a Versatile Tool for Exogenous Protein Expression. Current Gene Therapy, 2012, 12, 347-361.	0.9	57
72	Dendritic cell therapy for Type 1 diabetes suppression. Immunotherapy, 2012, 4, 1063-1074.	1.0	15
73	Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunology, Immunotherapy, 2012, 61, 2003-2011.	2.0	24

#	Article	IF	Citations
75	Trial watch. OncoImmunology, 2012, 1, 1111-1134.	2.1	152
76	Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation. Immunotherapy, 2012, 4, 703-718.	1.0	40
77	Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials. Immunotherapy, 2012, 4, 1031-1042.	1.0	9
78	In Vivo Imaging of Lymph Node Migration of MNP- and 111In-Labeled Dendritic Cells in a Transgenic Mouse Model of Breast Cancer (MMTV-Ras). Molecular Imaging and Biology, 2012, 14, 183-196.	1.3	19
79	Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens, 2012, 79, 147-154.	1.0	47
81	Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunology, Immunotherapy, 2013, 62, 1499-1509.	2.0	236
82	RNA pulsed dendritic cells: An approach for cancer immunotherapy. Vaccine, 2013, 31, 1141-1156.	1.7	30
83	Generation of Potent Cytotoxic <scp>T</scp> Lymphocytes Against Castrationâ€Resistant Prostate Cancer Cells by Dendritic Cells Loaded With Dying Allogeneic Prostate Cancer Cells. Scandinavian Journal of Immunology, 2013, 77, 117-124.	1.3	5
84	Vaccination with Antigen-Transfected, NKT Cell Ligandâ€“Loaded, Human Cells Elicits Robust In Situ Immune Responses by Dendritic Cells. Cancer Research, 2013, 73, 62-73.	0.4	37
85	mRNA. Human Vaccines and Immunotherapeutics, 2013, 9, 265-274.	1.4	49
86	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. Frontiers in Immunology, 2014, 5, 165.	2.2	127
87	Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?. Frontiers in Immunology, 2014, 5, 218.	2.2	12
88	Genetically Modified Dendritic Cell Vaccines for Solid Tumors. , 2014, , 273-282.		0
89	Immune escape of cancer cells with beta2â€microglobulin loss over the course of metastatic melanoma. International Journal of Cancer, 2014, 134, 102-113.	2.3	129
90	Dendritic Cell Vaccination. , 2014, , 283-300.		0
91	Ex Vivo Gene Therapy. , 2014, , 3-18.		2
93	Immunotherapy in Veterinary Oncology. Veterinary Clinics of North America - Small Animal Practice, 2014, 44, 925-939.	0.5	7
94	mRNA-based therapeutics â€" developing a new class of drugs. Nature Reviews Drug Discovery, 2014, 13, 759-780.	21.5	1,501

#	Article	IF	Citations
95	Ribonucleic acid purification. Journal of Chromatography A, 2014, 1355, 1-14.	1.8	54
96	Clinical use of dendritic cells for cancer therapy. Lancet Oncology, The, 2014, 15, e257-e267.	5.1	565
97	Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. Wiley Interdisciplinary Reviews RNA, 2015, 6, 471-499.	3.2	65
98	Precision Cancer Immunotherapy. Journal of Immunotherapy, 2015, 38, 155-164.	1.2	25
99	Whole Tumor Antigen Vaccines: Where Are We?. Vaccines, 2015, 3, 344-372.	2.1	203
100	Immunotherapy of Cancer â€" Some Up-To-Date Approaches. , 2015, , .		0
101	The importance of comparative oncology in translational medicine. Cancer Immunology, Immunotherapy, 2015, 64, 137-148.	2.0	34
102	Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 773-781.	0.8	501
103	Synergism between cryoablation and GM-CSF. NeuroReport, 2015, 26, 346-353.	0.6	17
104	A novel recombinant protein of ephrinA1â€"PE38/GM-CSF activate dendritic cells vaccine in rats with glioma. Tumor Biology, 2015, 36, 5497-5503.	0.8	6
105	Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca2+ transport ATPase 2 regulation. Cytotherapy, 2015, 17, 1421-1433.	0.3	15
106	Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. Cancer Immunology, Immunotherapy, 2015, 64, 1609-1621.	2.0	42
107	mRNA-based dendritic cell vaccines. Expert Review of Vaccines, 2015, 14, 161-176.	2.0	121
108	Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 87-105.	3.3	96
109	mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. OncoImmunology, 2016, 5, e1207842.	2.1	29
110	Dendritic cell vaccines for melanoma: past, present and future. Melanoma Management, 2016, 3, 273-289.	0.1	20
111	Past, present and forecast of transfusion medicine: What has changed and what is expected to change?. Presse Medicale, 2016, 45, e253-e272.	0.8	2
112	mRNA-based therapeuticsâ€"Advances and perspectives. Biochemistry (Moscow), 2016, 81, 709-722.	0.7	49

#	Article	IF	Citations
113	Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. OncoImmunology, 2016, 5, e1232237.	2.1	38
115	Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T). Future Oncology, 2016, 12, 751-762.	1.1	18
116	In situ dendritic cell vaccination for the treatment of glioma and literature review. Tumor Biology, 2016, 37, 1797-1801.	0.8	4
117	Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunology, Immunotherapy, 2017, 66, 891-901.	2.0	71
118	Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA. Tumor Biology, 2017, 39, 101042831773336.	0.8	21
119	Hematologic neoplasms: Dendritic cells vaccines in motion. Clinical Immunology, 2017, 183, 181-190.	1.4	17
120	Generation of potent cytotoxic T lymphocytes against in male patients with non-muscle invasive bladder cancer by dendritic cells loaded with dying T24 bladder cancer cells. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 615-627.	0.7	7
121	Veterinary Oncology Immunotherapies. Veterinary Clinics of North America - Small Animal Practice, 2018, 48, 257-277.	0.5	8
122	Dendritic Cells: The Tools for Cancer Treatment. , 0, , .		4
123	Cancer Immunology. , 2018, , 409-419.		0
124	Preservation of cell-based immunotherapies for clinical trials. Cytotherapy, 2019, 21, 943-957.	0.3	70
125	Role of Interferon (IFN)Î± in â€œCocktailsâ€•for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions. Journal of Immunotherapy, 2019, 42, 143-161.	1.2	13
126	Immune Cell Vaccine forÂCancer. , 2019, , 117-127.		1
127	Induction of T cell-mediated immune response by dendritic cells pulsed with mRNA of sphere-forming cells isolated from patients with gastric cancer. Life Sciences, 2019, 219, 136-143.	2.0	19
128	Genetic Vaccine for Cancer. , 2019, , 129-143.		0
129	Dendritic cells as cancer therapeutics. Seminars in Cell and Developmental Biology, 2019, 86, 77-88.	2.3	50
130	Advances in Development of mRNA-Based Therapeutics. Current Topics in Microbiology and Immunology, 2020, , 1.	0.7	6
131	Antitumour dendritic cell vaccination in a priming and boosting approach. Nature Reviews Drug Discovery, 2020, 19, 635-652.	21.5	148

#	Article	IF	Citations
132	Enzymatic Protein Biopolymers as a Tool to Synthetize Eukaryotic Messenger Ribonucleic Acid (mRNA) with Uses in Vaccination, Immunotherapy and Nanotechnology. Polymers, 2020, 12, 1633.	2.0	7
133	A review on development of MUC1-based cancer vaccine. Biomedicine and Pharmacotherapy, 2020, 132, 110888.	2.5	73
134	Combining chemotherapy and autologous peptideâ€pulsed dendritic cells provides survival benefit in stageÂIV melanoma patients. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1270-1277.	0.4	2
136	Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives. Nanomaterials, 2020, 10, 364.	1.9	138
137	Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cellsâ€"An Update. Pharmaceutics, 2020, 12, 92.	2.0	46
138	Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready â€˜N Able to Improve Clinical Outcome?. Cancers, 2020, 12, 299.	1.7	2
139	Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines. Current Opinion in Biotechnology, 2020, 65, 142-155.	3.3	12
140	Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials, 2021, 266, 120431.	5.7	131
141	Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opinion on Biological Therapy, 2021, 21, 201-218.	1.4	55
142	Clinical and immunological effects of mRNA vaccines in malignant diseases. Molecular Cancer, 2021, 20, 52.	7.9	90
143	mRNA therapeutics in cancer immunotherapy. Molecular Cancer, 2021, 20, 69.	7.9	168
144	mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. Vaccines, 2021, 9, 1060.	2.1	39
145	The Use of Dendritic Cells for Peptide-Based Vaccination in Cancer Immunotherapy. Methods in Molecular Biology, 2014, 1139, 479-503.	0.4	18
146	Immunotherapy of Cancer with Dendritic Cells Loaded with Tumor Antigens and Activated Through mRNA Electroporation. Methods in Molecular Biology, 2010, 629, 403-450.	0.4	24
147	Examination of MARCO Activity on Dendritic Cell Phenotype and Function Using a Gene Knockout Mouse. PLoS ONE, 2013, 8, e67795.	1.1	11
148	Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology. PLoS ONE, 2016, 11, e0152384.	1.1	2
149	Immunotargeting of Melanoma. , 0, , .		1
150	Gentherapie. , 2008, , 379-394.		0

#	Article	IF	Citations
152	Dendritic Cells. , 2010, , 807-854.		0
153	Dendritic Cell-Based Cancer Vaccines: Practical Considerations. , 2011, , 107-126.		0
154	Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts. , 2013, , 71-108.		0
155	Dendritic Cell-Based Cancer Vaccines. , 2014, , 69-87.		0
157	Inmunoterapia en melanoma: vacunas de cÃ©lulas dendrÃticas. Revista Peruana De Medicina De Experimental Y Salud Publica, 2015, 32, 555.	0.1	0
159	mRNA, a Revolution in Biomedicine. Pharmaceutics, 2021, 13, 2090.	2.0	26
160	mRNA cancer vaccines: Advances, trends and challenges. Acta Pharmaceutica Sinica B, 2022, 12, 2969-2989.	5.7	55
161	The current clinical landscape of personalized cancer vaccines. Cancer Treatment Reviews, 2022, 106, 102383.	3.4	25
162	Tumor cell-based vaccine: an effective strategy for eradication of cancer cells. Immunotherapy, 2022, 14, 639-654.	1.0	25
163	Dendritic cell transfer for cancer immunotherapy. International Review of Cell and Molecular Biology, 2022, , 33-64.	1.6	7
164	Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases. Frontiers in Immunology, 0, 13, .	2.2	7
165	Nonlysosomal Route of mRNA Delivery and Combining with Epigenetic Regulation Optimized Antitumor Immunoprophylactic Efficacy. Advanced Healthcare Materials, 2023, 12, .	3.9	5
166	Advances of mRNA vaccine in tumor: a maze of opportunities and challenges. Biomarker Research, 2023, 11, .	2.8	12
167	Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development. Pathogens, 2023, 12, 138.	1.2	15
168	Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects. Vaccines, 2023, 11, 636.	2.1	9
172	mRNA vaccines in disease prevention and treatment. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	9